Nanotechnology in gynaecological cancers: Biomedical perspectives on lipid-based drug delivery systems for targeted therapy.

The cervix, uterus, fallopian tubes, and ovaries are among the vital reproductive organs housed in the female upper genital tract (UGT). These organ systems are impacted by a number of pathologies, including cancer, inflammatory disorders, structural abnormalities, infections, and reproductive problems, leading to health of women. The neoplasia, ovarian, uterine and fallopian tube cancers are still remaining challenging for female reproductive health. The existing treatment still have drawbacks including reoccurrence and not completely cure, which shows burden on woman health and survival. As a cutting-edge field, nanotechnology offers novel approaches to the management and treatment of disorders affecting the female reproductive system by enabling the exact manipulation and regulation of biological molecules and cells. Lipid-based drug delivery systems offer a promising approach for advanced management of gynaecological cancers by enhancing drug solubility, stability, and targeted delivery. Their biocompatibility and ability to reduce systemic toxicity make them ideal for improving therapeutic outcomes in ovarian, cervical, and endometrial cancers. Biomedical insights into gynaecological cancers have significantly advanced our understanding of tumor biology, molecular pathways, and resistance mechanisms. This knowledge enables the identification of specific biomarkers and therapeutic targets, paving the way for personalized and targeted treatment strategies. Integrating these insights with nanotechnology, particularly lipid-based systems, enhances the precision and efficacy of cancer therapy in gynaecological malignancies. This review highlights recent advancements in lipid-based nanocarriers, emphasizing their biomedical relevance and therapeutic potential in the targeted management of prevalent gynaecological cancers.